Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
diseases_banner
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
  Uveitis  
HOME >> Diseases >> Diseases Index >> Index U >> Uveitis
 Uveitis  

 

 


What is Uveitis?

Uveitis consists of a group of diseases characterized by significant sight threatening intraocular inflammation primarily involving the uveal tract (iris, ciliary body, and choroid), although inflammation of adjacent tissues, such as retina, optic nerve, and vitreous humor also occurs.

Little is known about the pathogenesis of uveitis, but in cases of endogenous uveitis in which no link with an infectious agent can be identified, autoimmunity has been invoked as the cause. Many cases are often labelled as idiopathic, but in some it may be part of systemic disease process, such as sarcoidosis, multiple sclerosis, and Behçet’s disease, or associated with the HLA-B27 positive group of diseases. Infectious agents, such as the herpes group of viruses, toxoplasma gondii, mycobacterium tuberculosis, and treponema pallidum are also well-recognized causes.

Uveitis mainly occurs in the 20-50 year age group, and can affect one or both eyes. The incidence of uveitis varies from 14 to 52.4/100,000 with the overall prevalence around the world is up to 0.73%. A recent study found that the extrapolated 10-year incidence of uveitis was almost three times higher than that reported almost 40 years previously. Most uveitis patients present at an age where they are in the most active period of their working life. In about half the patients the age of onset is in the third or fourth decade of life. This age distribution makes uveitis a group of ocular diseases with an important socioeconomic impact.

Many cases will resolve rapidly, but a significant number of patients develop persistent disease with inflammatory damage to ocular structures resulting in severe visual impairment. The main causes of sight loss are cystoid macular edema, cataract, and glaucoma.

Approximately 5-20% of legal blindness in developed countries is due to uveitis, and it has been estimated that uveitis accounts for 10-15% of all cases of total blindness in the USA. Acute anterior uveitis is the commonest subtype and carries the best visual outcome, with a worse visual prognosis seen in patients with posterior uveitis and panuveitis.

In non-infectious causes, therapy is usually aimed at dampening down the immune response with corticosteroids being the first line treatment. In sight threatening disease immunosuppressive agents may need to be added to improve or preserve sight.

what are the Symptoms?
Uveitis can affect one or both eyes. Symptoms may develop rapidly and can include:
* Blurred vision
*Dark, floating spots in the vision
* Eye pain
* Redness of the eye
* Sensitivity to light

Signs and tests
A complete medical history and eye examination should be performed. Laboratory tests may be done to rule out infection or an autoimmune disorder.
Persons over age 25 with pars planitis should have an MRI of their brain and spine to rule out multiple sclerosis.

what are the Treatment?
Iritis is usually mild. Treatment may involve:
* Dark glasses
* Eye drops that dilate the pupil to relieve pain
* Steroid eye drops
Pars planitis is often treated with steroid eye drops. Other medicines, including steroids taken by mouth, may be prescribed to help suppress the immune system.
Posterior uveitis treatment depends on the underlying cause but almost always includes steroids taken by mouth. Additional specialists in infectious disease or autoimmunity may be needed for such diseases as syphilis, tuberculosis, AIDS, sarcoidosis, or Behcet syndrome.
If the uveitis is caused by a body-wide infection, treatment may involve antibiotics and powerful anti-inflammatory medicines called corticosteroids. See autoimmune disorders for information on treating such diseases.

Expectations (prognosis)
With proper treatment, most attacks of anterior uveitis go away in a few days to weeks. However, relapses are common.
Inflammation related to posterior uveitis may last from months to years and may cause permanent vision damage, even with treatment.

Complications
* Cataracts
* Fluid within the retina
* Glaucoma
* Retinal detachment
* Vision loss
 

 


  Growing Stronger, Growing
  Better
medicine
 
  Global Health
 
world
 
  Healthcare Provider
 
Healthcare Provider






 

 

 

 

 

 

 

 

 

 

 

 

 

 








 

 

 

Uveitis - treatment of Uveitis, Uveitis types, Disease medicines, Uveitis symptoms, Uveitis and Disease symptoms, Uveitis symptoms Disease and diagnosis, Symptoms and Solutions, Signs and Symptoms, type of Uveitis, cause common, common Uveitis, Uveitis List, causes list, Infectious Uveitis, Causes, Diseases , Types, Prevention, Treatment and Facts, Uveitis information, Uveitis: Definition, Uveitis names, medical Uveitis, medical Uveitis and disorders, cell Uveitis, Uveitis Worldwide, Uveitis Research, Uveitis Control, Uveitis Center, Digestive Uveitis Week, Information about Uveitis, causes of different Uveitis, Uveitis Articles, Uveitis and conditions, Health and Uveitis, Uveitis Patients, Uveitis and Sciences, causes of alzheimer's Uveitis, Uveitis causes, alternative medicine heart Uveitis, body ailments, Uveitis medicines, medical antiques, type of blood Uveitis  
 
   
diseases
  diseases index
 
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
   
  RESEARCH & DEVELOPMENT
  CONSUMER CARE
  MEDICAL CARE
  ANIMAL HEALTH
  TECHNOLOGY
  SOCIAL RESPONSIBILITY
  DRUGS INFORMATION
  FIRST AID & EMERGENCY GUIDE
  DIET & NUTRITION
  AMAZING BODY FACTS
 
YOGA FOR HEALTH

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 www.tajpharma.com

 

   
 

               
 Print page   Send by mail

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement